# Spacio-Linear Screening for Ligand-Docking Cavities in Protein Structures: SLAM Algorithm

**Authors:** Julia Panov, Alexander Elbert, Dean S. Rosenthal, Moshe Levi, Konstantin Chumakov, Raul Andino, Leonid Brodsky, Hanoch Kaphzan

PMC · DOI: 10.3390/life16020285 · 2026-02-07

## TL;DR

SLAM is a new algorithm that identifies similar ligand-binding sites in proteins, helping with drug repurposing and understanding protein-ligand interactions.

## Contribution

SLAM introduces a novel alignment-based method for detecting 3D similarities in ligand-binding cavities with improved sensitivity and scalability.

## Key findings

- SLAM outperforms ProBiS in true-positive rate for ligand-docking compatibility prediction.
- SLAM identifies candidate ligands for CRISPR-Cas proteins and novel PFAS binding partners.
- SLAM is computationally efficient and detects subtle physicochemical compatibilities between protein surfaces.

## Abstract

Identifying structurally similar ligand-binding sites in unrelated proteins can facilitate drug repurposing, reveal off-target effects, and deepen our understanding of protein function. A number of tools were developed for structural screening, but many of them suffer from limited sensitivity and scalability. Using a data bank of crystallized protein structures, we aimed to discover novel protein targets for a ligand by leveraging a known ligand-binding query protein with a resolved structure. Here, we present SLAM (Spacio-Linear Alignment of Macromolecules), a novel alignment-based algorithm that detects local 3D similarities between ligand-binding cavities or protein-exposed surfaces of query and target proteins. SLAM encodes spatial substructure neighborhoods into short linear sequences of physicochemically annotated atoms, then applies pairwise sequence alignment combined with distance-correlation scoring to identify high-fidelity structural matches. Benchmarking using the Kahraman-36 dataset demonstrated that SLAM outperforms the state-of-the-art ProBiS algorithm in true-positive rate for predicting ligand-docking compatibility. Furthermore, SLAM identifies candidate ligands that may inhibit functionally critical domains of CRISPR-Cas proteins and predicts novel binding partners of toxic per- and polyfluoroalkyl Substance (PFAS) compounds (PFOA, PFOS) with plausible mechanistic links to toxicity. In conclusion, SLAM is a robust computationally efficient and flexible structural screening tool capable of detecting subtle physicochemical compatibilities between protein surfaces, promising to accelerate target discovery in pharmacology and elucidate protein–ligand interactions in environmental toxicology.

## Linked entities

- **Chemicals:** PFOA (PubChem CID 9554), PFOS (PubChem CID 74483)

## Full-text entities

- **Genes:** AR (androgen receptor) [NCBI Gene 367] {aka AIS, AR8, DHTR, HPCX3, HUMARA, HYSP1}, ACR (acrosin) [NCBI Gene 49] {aka SPGF87}, TRPC6 (transient receptor potential cation channel subfamily C member 6) [NCBI Gene 7225] {aka FSGS2, TRP6}, FABP3 (fatty acid binding protein 3) [NCBI Gene 2170] {aka FABP11, H-FABP, M-FABP, MDGI, O-FABP}, SLAMF1 (signaling lymphocytic activation molecule family member 1) [NCBI Gene 6504] {aka CD150, CDw150, IPO3, SLAM}, PDB [NCBI Gene 5131], SELPLG (selectin P ligand) [NCBI Gene 6404] {aka CD162, CLA, PSGL-1, PSGL1}, BCAR1 (BCAR1 scaffold protein, Cas family member) [NCBI Gene 9564] {aka CAS, CAS1, CASS1, CRKAS, P130Cas}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, TTR (transthyretin) [NCBI Gene 7276] {aka AMYLD1, ATTR, CTS, CTS1, HEL111, HsT2651}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, KCNK9 (potassium two pore domain channel subfamily K member 9) [NCBI Gene 51305] {aka BIBARS, K2p9.1, KT3.2, TASK-3, TASK3, TASK32}, HMOX1 (heme oxygenase 1) [NCBI Gene 3162] {aka HMOX1D, HO-1, HSP32, bK286B10}, P3H3 (prolyl 3-hydroxylase 3) [NCBI Gene 10536] {aka GRCB, HSU47926, LEPREL2}, PFAS (phosphoribosylformylglycinamidine synthase) [NCBI Gene 5198] {aka FGAMS, FGAR-AT, FGARAT, GATD8, PURL}, PYGL (glycogen phosphorylase L) [NCBI Gene 5836] {aka GSD6}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}
- **Diseases:** fibrosis (MESH:D005355), injury to (MESH:D014947), cancers (MESH:D009369), chronic kidney disease (MESH:D051436), kidney and testicular cancer (MESH:D007680), immune system dysfunction (MESH:D007154), infections (MESH:D007239), toxicity (MESH:D064420), kidney disease (MESH:D007674), thyroid disease (MESH:D013959), TPs (MESH:C579935), cardiac dysfunction (MESH:D006331), liver damage (MESH:D056486)
- **Chemicals:** sulfate ion (MESH:D013431), phosphate ion (MESH:D010710), Per- and polyfluoroalkyl substances (MESH:D005466), glycogen (MESH:D006003), PFOA (MESH:C023036), cholesterol (MESH:D002784), cholesterol hemisuccinate (MESH:C013440), DABE (-), amino acid (MESH:D000596), HEM (MESH:D006418), FAD (MESH:D005182), Chlorophyll A (MESH:D000077194), FMN (MESH:D005486), ATP (MESH:D000255), AMP (MESH:D000249), lipid (MESH:D008055), Hydrogen (MESH:D006859), PFOS (MESH:C076994), calcium (MESH:D002118), ROS (MESH:D017382), nr (MESH:C018613)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Pagrus pagrus (common sea bream, species) [taxon 8173], Homo sapiens (human, species) [taxon 9606]

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12942009/full.md

---
Source: https://tomesphere.com/paper/PMC12942009